کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8453490 | 1547904 | 2016 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
monomethyl auristatin EPLT2-CdAANCaggressive systemic mastocytosisASMALCLHCTTWCADCORRMMAEIFN-α2-ChlorodeoxyadenosineBrentuximab vedotin - Brentuximab VedotinSystemic mastocytosis - استاتوسیتوز سیستمیکimmunoconjugates - ایمونوکونژوگه هاInterferon-α - اینترفرون-αAbsolute neutrophil count - تعداد نوتروفیل مطلقcomputed tomography - توموگرافی کامپیوتری یا سی تی اسکن یا مقطعنگاری رایانهایPlatelet count - شمارش پلاکتGranulocyte colony stimulating factor - عامل تحریک کننده کلنی گرانولسیتیکG-CSF - فاکتور محرک کُلونی گرانولوسیتAnaplastic large cell lymphoma - لنفوم سلول بزرگ انعطاف پذیرHodgkin’s lymphoma - لنفوم هوچکینMast cells - ماست سل هاbone marrow - مغز استخوانHematologic neoplasms - نئوپلاسم های هماتولوژیکobjective response rate - نرخ پاسخ هدفhematocrit - هماتوکریتHemoglobin - هموگلوبینHgb - هورمون رشدpolymerase chain reaction - واکنش زنجیره ای پلیمرازPCR - واکنش زنجیرهٔ پلیمرازClinical trial - کارآزمایی بالینیAntibody-drug conjugate - کنگره آنتی بادی دارو
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin](/preview/png/8453490.png)
چکیده انگلیسی
Systemic mastocytosis is a myeloproliferative neoplasm with varying presentation that is caused by infiltration of neoplastic mast cells into extracutaneous tissues. Cytoreductive therapy is used to control organ dysfunction in aggressive systemic mastocytosis and is sometimes needed for control of severe refractory symptoms in patients with indolent disease. However, current standard cytoreductive agents are limited by their suboptimal degree and duration of response and associated significant toxicities, highlighting the need for novel treatments for systemic mastocytosis. Recent studies have identified CD30 as a therapeutic target in systemic mastocytosis, as CD30 is expressed on a majority of neoplastic mast cells. In this case series, the clinical outcomes of 4 patients with aggressive or indolent systemic mastocytosis treated with the anti-CD30 antibodyâdrug conjugate brentuximab vedotin are reported. Two patients showed evidence of a response to treatment with a reduction in disease burden, 1 of which has demonstrated a durable response with ongoing benefit for more than 3 years. Treatment with brentuximab vedotin was well-tolerated with side effects that were effectively managed by dose modifications. The results presented suggest that brentuximab vedotin is active in systemic mastocytosis and can induce durable responses with a manageable toxicity profile.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 44, May 2016, Pages 25-31
Journal: Leukemia Research - Volume 44, May 2016, Pages 25-31
نویسندگان
Uma Borate, Amitkumar Mehta, Vishnu Reddy, Michaela Tsai, Neil Josephson, Ian Schnadig,